"Hypogonadism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Descriptor ID |
D007006
|
| MeSH Number(s) |
C19.391.482
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hypogonadism".
Below are MeSH descriptors whose meaning is more specific than "Hypogonadism".
This graph shows the total number of publications written about "Hypogonadism" by people in this website by year, and whether "Hypogonadism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 5 | 0 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 4 | 1 | 5 |
| 2012 | 7 | 0 | 7 |
| 2013 | 7 | 1 | 8 |
| 2014 | 14 | 2 | 16 |
| 2015 | 9 | 3 | 12 |
| 2016 | 10 | 2 | 12 |
| 2017 | 11 | 3 | 14 |
| 2018 | 8 | 4 | 12 |
| 2019 | 5 | 2 | 7 |
| 2020 | 10 | 2 | 12 |
| 2021 | 9 | 3 | 12 |
| 2022 | 5 | 0 | 5 |
| 2023 | 6 | 0 | 6 |
| 2024 | 5 | 1 | 6 |
| 2025 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypogonadism" by people in Profiles.
-
Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025 Oct 04; 13(4):548-573.
-
Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study. J Sex Med. 2025 Sep 04; 22(9):1564-1571.
-
Testosterone deficiency and treatments: common misconceptions and practical guidance for patient care. Sex Med Rev. 2025 Jul 03; 13(3):373-380.
-
Hypogonadism in Fathers and Perinatal Outcomes in Offspring: A Retrospective Analysis of U.S. Claims Data. Urology. 2025 07; 201:62-67.
-
Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e814-e826.
-
Testosterone Modulation of Muscle Transcriptomic Profile During Lifestyle Therapy in Older Men with Obesity and Hypogonadism. J Cachexia Sarcopenia Muscle. 2025 Feb; 16(1):e13697.
-
PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/?-CATENIN Pathway in Testosterone-Treated Hypogonadal Men. Biomolecules. 2025 Jan 08; 15(1).
-
Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury. J Sex Med. 2024 12 01; 21(12):1201-1203.
-
Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology. 2025 May; 13(4):882-893.
-
A PRDM16-driven signal regulates body composition in testosterone-treated hypogonadal men. Front Endocrinol (Lausanne). 2024; 15:1426175.